Prognostic and predictive value of PDL1 expression in breast cancer.
about
The efficacy and potential predictive factors of PD-1/PD-L1 blockades in epithelial carcinoma patients: a systematic review and meta analysisCheckpoint Inhibitors and Their Application in Breast CancerTumor-Infiltrating Lymphocytes in Triple Negative Breast Cancer: The Future of Immune TargetingThe effect of chemotherapy on programmed cell death 1/programmed cell death 1 ligand axis: some chemotherapeutical drugs may finally work through immune responseBiological network-driven gene selection identifies a stromal immune module as a key determinant of triple-negative breast carcinoma prognosis.Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyondEnhanced killing of chordoma cells by antibody-dependent cell-mediated cytotoxicity employing the novel anti-PD-L1 antibody avelumab.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.Emerging therapies for breast cancerTriple-negative breast cancer: challenges and opportunities of a heterogeneous disease.New Immunotherapy Strategies in Breast Cancer.PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosisPDL1 expression in inflammatory breast cancer is frequent and predicts for the pathological response to chemotherapy.Monocyte and interferon based therapy for the treatment of ovarian cancer.Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.PD-L1 Status in Refractory Lymphomas.A Stromal Immune Module Correlated with the Response to Neoadjuvant Chemotherapy, Prognosis and Lymphocyte Infiltration in HER2-Positive Breast Carcinoma Is Inversely Correlated with Hormonal Pathways.Endocrine resistance in breast cancer--An overview and update.High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.The Impact of PD-L1 Expression in Patients with Metastatic GEP-NETs.PD-L1 Expression Is Associated with Tumor FOXP3(+) Regulatory T-Cell Infiltration of Breast Cancer and Poor Prognosis of Patient.Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types.PD-L1 expression and CD274 gene alteration in triple-negative breast cancer: implication for prognostic biomarker.Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer.Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer.Therapeutic efficacy of PD-L1 blockade in a breast cancer model is enhanced by cellular vaccines expressing B7-1 and glycolipid-anchored IL-12.Expression of Programmed Death Receptor Ligand 1 with High Tumor-Infiltrating Lymphocytes Is Associated with Better Prognosis in Breast CancerThe Clinical Significance of CD169-Positive Lymph Node Macrophage in Patients with Breast Cancer.Molecular and clinical characterization of PD-L1 expression at transcriptional level via 976 samples of brain glioma.Predictive factors of the tumor immunological microenvironment for long-term follow-up in early stage breast cancerPrognostic value of PDL1 expression in pancreatic cancerProgrammed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.Targeting of interleukin (IL)-17A inhibits PDL1 expression in tumor cells and induces anticancer immunity in an estrogen receptor-negative murine model of breast cancerPD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma.Mechanism of immune evasion in breast cancer.The combination of PD-L1 expression and decreased tumor-infiltrating lymphocytes is associated with a poor prognosis in triple-negative breast cancer.Soluble programmed death-ligand 1 (sPDL1) and neutrophil-to-lymphocyte ratio (NLR) predicts survival in advanced biliary tract cancer patients treated with palliative chemotherapy.Epigenetic modulation with histone deacetylase inhibitors in combination with immunotherapy.Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1.
P2860
Q26740280-FCE18212-5EE5-4B8B-BA21-0C169379E169Q26745442-C6CB46C2-CF4C-4316-AAE9-FAE0E9E2E981Q26747792-088D9917-B449-4046-95F1-4EC785E7891FQ26766066-62C202A3-1BAC-46BF-9661-45A69C5F584CQ27311085-55C1CB5C-784E-4E07-A64D-8498D1622F36Q28077815-BBB6DEF2-B638-41BD-A4E9-9D81D84ABC36Q33276035-FA7CFA26-8910-4866-BC3D-61F933F85A87Q33589487-D6FDECAA-1527-498E-8D3E-803EA09ADF60Q33617949-5ED473FB-8729-42B1-908D-5A3392F5B00CQ33769821-25EB3CCF-8084-4E0D-B240-166E9C169972Q34549227-4D9E6E5A-124D-449D-9FEA-C3F9E338F256Q35809165-503D73C4-DCCF-49A6-AE44-4FAC76C59B78Q35955369-8BC9BEFC-E9AA-4568-8C95-1C2E94DA2AA2Q35973378-B94407D5-9B2A-4B3B-94C3-28A8927EC6B4Q36030084-96247A3D-E432-40A2-B0B7-AF7AAC485718Q36197517-E3EDF420-C27F-4682-944A-258BD24DAEADQ36231343-2DFE5695-1F5F-49CC-B6C7-15A1256CDF7EQ36386322-7F6EA3B2-63DD-4D4B-9029-CCE0684C12EAQ36545353-8C9B3000-5128-40DD-B53A-FAD8029571E7Q36657306-58064F2E-CF85-45AB-89B1-374136C8E49CQ36882550-87332D21-154A-477F-940C-FF6D34F66F53Q36939402-B3B6A366-E6BE-43D9-87E9-31A2E704EE30Q37026725-36607437-3F02-4ED3-8EE4-BE1ED8954595Q37138871-0D8F4B27-3C0D-416F-B0B0-E306380F28EAQ37199510-37CACE39-5EE9-4D37-BAB8-7B36DFD72DA7Q37309250-3A1F3BFC-506D-4083-8800-6EF70EDC8DBCQ37316596-EF1EC0EC-F469-4906-89E8-F1E648A87930Q37423348-E8845F43-8864-4E2F-8A3C-A202D47B916AQ37477267-62BFFD4A-251D-40F1-86F5-28A6D3FD0887Q37611683-4765AE68-C342-4E21-82C9-6AA6F307FEE5Q37687595-162F865C-EDED-4D88-B9DB-8C84426AA245Q37691082-A5C8E6E0-4DC5-4B9A-B18E-2F9F01B2A7D3Q37702580-9A8B432E-7AB6-4138-80DF-6A8D6587FC44Q37705021-1C789D6D-7033-45BF-AE04-7D0BE74D6B62Q37712385-5E8BD51E-ADCF-444E-BF7C-F30DCA1537DFQ37716582-859FB282-933C-490F-A5D6-0623E4B14A4EQ37718250-5E987B77-90FD-49D4-888E-023E6AACD814Q38537768-A69083E5-6896-4E30-ABD4-4E8594D64810Q38610333-B665DEFF-C4B1-4C4C-9B9E-B24C98E524E4Q38629357-9A64F2E0-B2EE-4C43-8211-721441AA8C52
P2860
Prognostic and predictive value of PDL1 expression in breast cancer.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Prognostic and predictive value of PDL1 expression in breast cancer.
@ast
Prognostic and predictive value of PDL1 expression in breast cancer.
@en
type
label
Prognostic and predictive value of PDL1 expression in breast cancer.
@ast
Prognostic and predictive value of PDL1 expression in breast cancer.
@en
prefLabel
Prognostic and predictive value of PDL1 expression in breast cancer.
@ast
Prognostic and predictive value of PDL1 expression in breast cancer.
@en
P2093
P2860
P50
P356
P1433
P1476
Prognostic and predictive value of PDL1 expression in breast cancer.
@en
P2093
Carlos Caldas
Daniel Birnbaum
Emilie Mamessier
François Bertucci
Hamid Raza Ali
José Adelaide
Pascal Finetti
P2860
P304
P356
10.18632/ONCOTARGET.3216
P407
P577
2015-03-01T00:00:00Z